Canopy Growth to acquire MTL Cannabis

Executive Summary

• Canopy Growth entered a definitive arrangement agreement to acquire all outstanding shares of MTL Cannabis, valuing the transaction at ~ $125 million on a fully‑diluted equity basis (≈ $179 million enterprise value).
• Consideration per MTL share: 0.32 Canopy Growth common share plus C$0.144 cash; total consideration represents roughly a 45 % premium to the 20‑day VWAP.
• The deal is expected to be accretive, positioning Canopy as Canada’s leading medical‑cannabis provider, expanding its Quebec footprint, and adding high‑margin flower capacity for Canadian and European markets.

Key Details

• Transaction Structure – Court‑approved plan of arrangement under the Canada Business Corporations Act; requires two‑thirds shareholder approval plus a simple majority of excluded votes.
• Consideration – 0.32 Canopy share + C$0.144 cash per MTL share; ~137 million MTL shares outstanding → ≈ $125 M total equity consideration (excluding up to 2,956,391 additional Canopy shares issued for former MC shareholders).
• Lock‑up – Approximately 72 % of the newly issued Canopy shares are subject to staggered lock‑up periods (10 % after 3 mo, 20 % after 6 mo, 20 % after 9 mo, 50 % after 12 mo).
• Financial Impact – MTL’s trailing‑12‑month (TTM) results: $84 M revenue, 51 % gross margin (pre‑fair‑value), $11 M operating cash flow. Expected cost synergies ≈ $10 M annually over 18 months; transaction deemed materially accretive to Canopy’s adjusted EBITDA goal.
• Strategic Benefits –
• Elevates Canopy to the top position in Canada’s medical cannabis market (combined patient network, clinics, and online channel).
• Adds two Quebec cultivation facilities and the R’Belle brand, strengthening presence in Canada’s second‑largest market.
• Enhances flower supply for European medical markets and supports growth in Canadian adult‑use categories (MTL holds #1 share in upper‑midstream flower, #4 in prerolls).
• Management Retention – Key MTL executives (founders Richard & Michel Clement) will receive performance stock units (~ $2 M total); CEO Michael Perron to become Canopy COO with RSUs ($30k) and options ($20k).
• Shareholder Benefits – Premium of ~45 % over 20‑day VWAP; immediate liquidity via more actively traded Canopy shares (≈ $35 M average daily volume).
• Approvals & Closing – Unanimous board approvals; special committee fairness opinion from Haywood Securities. Expected closing before end‑February 2026, subject to court, shareholder, TSX, Competition Act and other regulatory consents.
• Advisers – Canaccord Genuity (financial adviser to Canopy); Cassels Brock & Blackwell LLP & Paul Hastings LLP (legal counsel to Canopy). Haywood Securities (financial adviser to MTL special committee) and Farris LLP (legal counsel to MTL).

Notable Quotes

• “MTL brings skilled operators, strong brands and a profitable business that will strengthen our leadership in Canada’s medical market…” – Luc Mongeau, CEO, Canopy Growth.
• “Joining Canopy Growth gives us the platform to bring this philosophy to more Canadians… we look forward to continuing to elevate Canadian cannabis.” – Richard Clement, Co‑founder & Chief Cultivation Officer, MTL Cannabis.